Ovid Therapeutics (OVID) EBIT Growth (1y) (2017 - 2026)
Ovid Therapeutics (OVID) EBIT Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.12 Bn | 466.33 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 121.84 Bn | 114.59 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 69.89 Bn | 61.14 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.64 Bn | 1.41 Bn | 145.20% |
| 9 | Alnylam Pharmaceuticals | 37.34 Bn | 34.34 Bn | 959.66 Mn | 1,386.07% |
| 10 | Ovid Therapeutics | 120.41 Mn | -35.11 Mn | - | -42.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.20% |
| Dec 31, 2025 | -14.65% |
| Sep 30, 2025 | 5.32% |
| Jun 30, 2025 | 75.27% |
| Mar 31, 2025 | 27.94% |
| Dec 31, 2024 | 41.05% |
| Sep 30, 2024 | -9.95% |
| Jun 30, 2024 | -44.77% |
| Mar 31, 2024 | -16.96% |
| Dec 31, 2023 | -49.41% |
| Sep 30, 2023 | 6.05% |
| Jun 30, 2023 | 0.92% |
| Mar 31, 2023 | 8.45% |
| Dec 31, 2022 | 53.81% |
| Sep 30, 2022 | -9.61% |
| Jun 30, 2022 | 0.06% |
| Mar 31, 2022 | -109.21% |
| Dec 31, 2021 | -22.06% |
| Sep 30, 2021 | 28.79% |
| Jun 30, 2021 | 38.15% |